Virchows Archiv

, Volume 449, Issue 3, pp 288–296 | Cite as

Routine assessment of prognostic factors in breast cancer using a multicore tissue microarray procedure

  • Anna Sapino
  • Caterina Marchiò
  • Rebecca Senetta
  • Isabella Castellano
  • Luigia Macrì
  • Paola Cassoni
  • Giampiero Ghisolfi
  • Milena Cerrato
  • Enrico D’Ambrosio
  • Gianni Bussolati
Original Article

Abstract

We propose multicore tissue microarray (TMA) as an alternative to whole section for routine assessment of prognostic factors in breast cancer. Since 2004, we introduced the multicore TMA for testing estrogen (ER) and progesterone receptors (PR), proliferation activity by Ki67, and HER2 overexpression and amplification in routine work. At least four tumor foci were selected on the whole section, and a dedicated technician used a stereomicroscope for accurate sampling of the selected areas. To identify a specific case in the TMA, a separate file and a computerized reporting form with the TMA map were created. A preliminary pilot study comparing the TMA results with those obtained on whole sections showed the specificity of the procedure. Moreover, in everyday diagnosis, hormone receptors were repeated on full section when negative in TMA, without significant discrepancy. Retrospective analysis of the 237 breast carcinomas studied by TMA showed the expected correspondence of tumor-grade differentiation with the hormone receptor pattern, the proliferation activity, and HER2 immunohistochemical and FISH values. In conclusion, multicore TMA may be an efficient approach in the routine study of prognostic factors in breast cancer, significantly reducing costs, time, and burden of slides necessary to accomplish these mandatory tests.

Keywords

Multicore TMA Diagnosis Prognostic factors 

Notes

Acknowledgements

This work was supported by grants from the Ministry for Universities, Instruction and Research (MIUR), Rome, Italy; MURST (ex 60%), Rome, Italy; the Compagnia di San Paolo/FIRMS, Torino, Italy, and Regione Piemonte “Ricerca Scientifica Applicata” 2004 (Decreto Dirigenziale 59).

References

  1. 1.
    Abd El-Rehim DM, Ball G, Pinder SE, Rakha E, Paish C, Robertson JF, Macmillan D, Blamey RW, Ellis IO (2005) High-throughput protein expression analysis using tissue microarray technology of a large well-characterised series identifies biologically distinct classes of breast cancer confirming recent cDNA expression analyses. Int J Cancer 116:340–350PubMedCrossRefGoogle Scholar
  2. 2.
    Bhargava R, Lal P, Chen B (2004) Feasibility of using tissue microarrays for the assessment of HER-2 gene amplification by fluorescence in situ hybridization in breast carcinoma. Diagn Mol Pathol 13:213–216PubMedCrossRefGoogle Scholar
  3. 3.
    Bubendorf L, Nocito A, Moch H, Sauter G (2001) Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195:72–79PubMedCrossRefGoogle Scholar
  4. 4.
    Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80:1943–1949PubMedCrossRefGoogle Scholar
  5. 5.
    Dhanasekaran SM, Barrette TR, Ghosh D, Shah R, Varambally S, Kurachi K, Pienta KJ, Rubin MA, Chinnaiyan AM (2001) Delineation of prognostic biomarkers in prostate cancer. Nature 412:822–826PubMedCrossRefGoogle Scholar
  6. 6.
    Ellis IO, Bartlett J, Dowsett M, Humphreys S, Jasani B, Miller K, Pinder SE, Rhodes A, Walker R (2004) Updated recommendations for HER2 testing in the UK. J Clin Pathol 57:233–237PubMedCrossRefGoogle Scholar
  7. 7.
    Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410PubMedCrossRefGoogle Scholar
  8. 8.
    Gillett CE, Springall RJ, Barnes DM, Hanby AM (2000) Multiple tissue core arrays in histopathology research: a validation study. J Pathol 192:549–553PubMedCrossRefGoogle Scholar
  9. 9.
    Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thurlimann B, Senn HJ; Panel members (2005) Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. Ann Oncol 16:1569–1583PubMedCrossRefGoogle Scholar
  10. 10.
    Kononen J, Bubendorf L, Kallioniemi A, Barlund M, Schraml P, Leighton S, Torhorst J, Mihatsch MJ, Sauter G, Kallioniemi OP (1998) Tissue microarrays for high-throughput molecular profiling of hundreds of specimens. Nat Med 4:844–847PubMedCrossRefGoogle Scholar
  11. 11.
    Lal P, Tan LK, Chen B (2005) Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas. Am J Clin Pathol 123:541–546PubMedCrossRefGoogle Scholar
  12. 12.
    Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K, Walker R (2000) Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The scottish breast cancer pathology group, and the receptor and biomarker study group of the eortc. J Clin Pathol 53:634–635PubMedCrossRefGoogle Scholar
  13. 13.
    Moch H, Kononen T, Kallioniemi OP, Sauter G (2001) Tissue microarrays: what will they bring to molecular and anatomic pathology? Adv Anat Pathol 8:14–20PubMedCrossRefGoogle Scholar
  14. 14.
    Nocito A, Kononen J, Kallioniemi OP, Sauter G (2001) Tissue microarrays (TMAs) for high throughput molecular pathology research. Int J Cancer 94:1–5PubMedCrossRefGoogle Scholar
  15. 15.
    Rosen DG, Huang X, Deavers MT, Malpica A, Silva EG, Liu J (2004) Validation of tissue microarray technology in ovarian carcinoma. Mod Pathol 17:790–797PubMedCrossRefGoogle Scholar
  16. 16.
    Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312–319PubMedCrossRefGoogle Scholar
  17. 17.
    Sapino A, Coccorullo Z, Cassoni P, Ghisolfi G, Gugliotta P, Bongiovanni M, Arisio R, Crafa P, Bussolati G (2003) Which breast carcinomas need HER-2/neu gene study after immunohistochemical analysis? Results of combined use of antibodies against different c-erbB2 protein domains. Histopathology 43:354–362PubMedCrossRefGoogle Scholar
  18. 18.
    Torhorst J, Bucher C, Kononen J, Haas P, Zuber M, Kochli OR, Mross F, Dieterich H, Moch H, Mihatsch M, Kallioniemi OP, Sauter G (2001) Tissue microarrays for rapid linking of molecular changes to clinical endpoints. Am J Pathol 159:2249–2256PubMedGoogle Scholar
  19. 19.
    Zhang D, Salto-Tellez M, Putti TC, Do E, Koay ES (2003) Reliability of tissue microarrays in detecting protein expression and gene amplification in breast cancer. Mod Pathol 16:79–84PubMedCrossRefGoogle Scholar
  20. 20.
    Zhang D, Salto-Tellez M, Do E, Putti TC, Koay ES (2003) Evaluation of HER2/neu oncogene status in breast tumors on tissue microarrays. Hum Pathol 34:362–368PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Anna Sapino
    • 1
  • Caterina Marchiò
    • 1
  • Rebecca Senetta
    • 1
  • Isabella Castellano
    • 1
  • Luigia Macrì
    • 1
  • Paola Cassoni
    • 1
  • Giampiero Ghisolfi
    • 1
  • Milena Cerrato
    • 1
  • Enrico D’Ambrosio
    • 2
  • Gianni Bussolati
    • 1
  1. 1.Department of Biomedical Sciences and Human OncologyUniversity of TurinTurinItaly
  2. 2.Division of PathologyVito Fazzi Hospital, Piazza F. MuratoreLecceItaly

Personalised recommendations